King Luther Capital Management Corp Lowers Holdings in Abbott Laboratories (NYSE:ABT)

King Luther Capital Management Corp trimmed its position in Abbott Laboratories (NYSE:ABT - Free Report) by 6.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,460,929 shares of the healthcare product maker's stock after selling 92,700 shares during the quarter. King Luther Capital Management Corp owned 0.08% of Abbott Laboratories worth $166,561,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in ABT. Ameriprise Financial Inc. raised its position in shares of Abbott Laboratories by 5.0% in the 2nd quarter. Ameriprise Financial Inc. now owns 10,675,827 shares of the healthcare product maker's stock worth $1,103,997,000 after acquiring an additional 508,524 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Abbott Laboratories by 27.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 7,428,752 shares of the healthcare product maker's stock worth $771,940,000 after acquiring an additional 1,596,835 shares in the last quarter. Diamond Hill Capital Management Inc. raised its position in shares of Abbott Laboratories by 8.5% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 6,683,586 shares of the healthcare product maker's stock worth $761,996,000 after acquiring an additional 524,683 shares in the last quarter. Swiss National Bank raised its position in shares of Abbott Laboratories by 0.5% in the 3rd quarter. Swiss National Bank now owns 5,163,580 shares of the healthcare product maker's stock worth $588,700,000 after acquiring an additional 26,000 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in Abbott Laboratories by 13.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 4,654,712 shares of the healthcare product maker's stock valued at $483,673,000 after buying an additional 563,506 shares in the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Robert B. Ford sold 141,679 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $116.41, for a total value of $16,492,852.39. Following the completion of the sale, the chief executive officer now owns 220,059 shares of the company's stock, valued at approximately $25,617,068.19. This trade represents a 39.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.47% of the company's stock.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $115.93 on Thursday. The company has a market capitalization of $201.08 billion, a P/E ratio of 35.24, a P/E/G ratio of 2.73 and a beta of 0.72. The business's 50 day moving average is $115.54 and its two-hundred day moving average is $109.74. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a 12-month low of $99.71 and a 12-month high of $121.64.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.01. The business had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $10.55 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.99%. The business's quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter last year, the business posted $1.14 earnings per share. Analysts expect that Abbott Laboratories will post 4.67 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, November 15th. Stockholders of record on Tuesday, October 15th were given a $0.55 dividend. The ex-dividend date of this dividend was Tuesday, October 15th. This represents a $2.20 annualized dividend and a dividend yield of 1.90%. Abbott Laboratories's dividend payout ratio (DPR) is presently 66.87%.

Analysts Set New Price Targets

ABT has been the topic of several recent analyst reports. Raymond James reaffirmed a "buy" rating and set a $129.00 target price (up from $122.00) on shares of Abbott Laboratories in a research report on Monday, October 14th. Morgan Stanley upped their target price on Abbott Laboratories from $107.00 to $117.00 and gave the company an "equal weight" rating in a research report on Thursday, October 17th. Sanford C. Bernstein increased their price objective on Abbott Laboratories from $133.00 to $138.00 and gave the company an "outperform" rating in a report on Thursday, October 17th. Royal Bank of Canada increased their price objective on Abbott Laboratories from $125.00 to $130.00 and gave the company an "outperform" rating in a report on Tuesday, October 8th. Finally, Piper Sandler Companies initiated coverage on Abbott Laboratories in a report on Thursday, September 19th. They issued an "overweight" rating and a $131.00 price objective on the stock. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $130.07.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.